Prof. Tracy Robson
Tracy Robson obtained her PhD in Cancer Biology from Imperial College, London. Her first academic post was as Lecturer in Radiation Science at Ulster University in 1997; she was promoted to Reader in 2001. She then moved to the School of Pharmacy, Queen’s University of Belfast in 2004 to take up the post of Reader in Molecular Pharmacology; she was promoted to Professor in 2010.
In 2016, she took up position as Professor and Head of Department of Molecular and Cellular Therapeutics at RCSI and then became Head of School of Pharmacy and Biomolecular Sciences in July 2019. Her major research focus has been the development of novel approaches for sensitizing tumours to therapy using personalised medicine approaches.
She led a major programme of research aimed at the identification and functional characterisation of genes that alter tumour response to anti-cancer agents. In particular, she cloned and characterized a novel human gene, FKBPL. Her group has demonstrated an extracellular role for FKBPL as a naturally secreted, anti-angiogenic protein.
Together with Almac, she led the development of therapeutic peptide derivatives (AD-01 and ALM201) based on FKBPL’s active anti-angiogenic domain. Based on the robust efficacy and excellent safety profile, ALM201, a ‘first-in-class’ FKBPL-based anti-angiogenic therapeutic peptide has completed formulation and toxicology testing and successfully completed a phase I cancer clinical trial (EudraCT number: 2014-001175-31). ALM201 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer.
More recently, through the development of genetically modified mouse models, she has also demonstrated a role for FKBPL in protection against a range of other diseases associated with vascular regulation and inflammation. She is actively researching in these areas, so that the clear translational potential of FKBPL-based therapeutics can be fully harnessed and FKBPL’s diagnostic potential in these disease settings can be scrutinized.
3D mammosphere culture of breast epithelial cell line MCF10A.
Courtesy of Dr. Emer Bourke, NUI Galway
Phospho-Akt expression and localisation
Mediated by VEGF in A549 lung cancer cells. Visualised by high content image analysis.
Metaphase chromosome spread of Jurkat T-lymphoma cells
Apoptosis assessment of SKMES-1 lung cancer cells
Using a multiparameter apoptosis staining kit, showing cell nuclei (blue), actin (green) and mitochondrial activity (orange).
Mitotic Chronic Myelogenous Leukaemia K562 Cells
Cell to Cell Tweeting
Via nanoparticles (red) in Triple Negative Breast Cancer (TNBC)
Courtesy of Sinéad Lindsay, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD) Ireland.
Confocal Microscopy Analysis
Of phospho-Akt expression in H460 lung cancer cells in response to hypoxia (0.5% O2).
IACR 2023 Carer’s Bursary €300
Apply for funding towards additional costs of care while attending conference. Five Bursaries Available.
Registration/ Membership for IACR 2023
Registration for the 59th Annual Conference in the Radisson Blu hotel, Athlone is Now Open.
EACR Membership is Included
The IACR is an affiliated national society and its members benefit from full membership of the EACR.
Biomedical Session Abstracts
Deadline: Midnight, Friday, 20th January 2023
- Patrick Johnston Lay submission category is now closed
- Late Breaking Abstracts submitted to the Biomedical Sessions will be considered for Display Poster Presentation.
Social Nursing and Allied Health (SNAH) Abstracts
Deadline: Midnight, Monday, 9th January 2023
SNAH abstract submissions will remain open until Monday 9th January.
Please contact Sinead on: firstname.lastname@example.org
Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations.
Registered Charity Number (RCN): 20030117